

**Freedom of Information Act 2000 – Request Reference FoI/23/582**

**Ovarian Cancer Treatment**

**Information Requested:**

Q1. How many patients have been treated for advanced (FIGO Stages III and IV) ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer over the last 3 months? If none, do you refer advanced ovarian cancer patients to another trust, and if so which one?

Q2. How many patients were treated in the past 3 months for ovarian cancer (any stage) with:

- Paclitaxel in combination with a platinum-based compound
- Platinum-based therapy alone (cisplatin or carboplatin)
- Bevacizumab in combination with paclitaxel and carboplatin
- Olaparib
- Olaparib + Bevacizumab
- Niraparib
- Rucaparib

Q3. If data for HRD (homologous recombination deficiency) testing is available, please provide how many HRD positive ovarian cancer patients were treated in the last 3 months with:

- Olaparib
- Olaparib + Bevacizumab
- Niraparib
- Other treatments

Q4. Does your trust participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part.

**Response Details:**

**In response to question 1:**

The below figures represent records where there are data entered on the final post-surgery stage. Please note that there is an entry lag for this data on the system.

Primary Diagnosis	Post-Surgery Stage Type	Total
Malig neop endomet corpus uter	FIGO	2
<b>Malig neop endomet corpus uter Total</b>		<b>2</b>
Malig neop ovary	FIGO	1
<b>Malig neop ovary Total</b>		<b>1</b>
<b>Grand Total</b>		<b>3</b>

**In response to questions 2–4:**

Cardiff and Vale University Health Board (the UHB) does not hold his information. However, as per our duty to advise and assist under section 16 of the Freedom of Information Act 2000, the UHB can refer you to the following link which you might find of use: [Velindre University NHS Trust: Freedom of Information](#).